Literature DB >> 9877031

The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide.

J S Strobl1, Z Melkoumian, V A Peterson, H Hylton.   

Abstract

Neuroleptic drugs that bind sigma sites were tested for their ability to inhibit growth and radiosensitize MCF-7 human breast cancer cells. Inhibition of growth by approximately 50% occurred in cells exposed to pimozide (0.6 microM), haloperidol (10 microM), and the sigma ligand DTG (1,3-di(2-tolyl)guanidine, 20 microM), but no growth inhibition occurred in cells exposed to clozapine, a neuroleptic drug lacking sigma binding activity, or dextromethorphan, a selective sigma 1 binding ligand. Pimozide (2.5 microM), but not haloperidol (3.6 microM), enhanced the sensitivity of MCF-7 cells to gamma radiation in clonogenic survival assays. Pimozide significantly decreased MCF-7 clonogenic survival following a 5 or 8 Gy dose of gamma radiation, and the dose of radiation required for 1% survival (survival enhancement ratio, SER) was decreased by a factor of 2. Exposure of normal WI-38 human embryonic lung cells to pimozide did not increase their sensitivity to gamma radiation. Pimozide (2.5 microM) activated early apoptotic changes in MCF-7 cells that were detected by the uptake of Hoechst 33342 dye, and 10 microM pimozide activated a complete apoptotic pathway resulting in the death of > 90% of the cells within 24 hours. MCF-7 cells exposed to gamma radiation alone (8 Gy) showed giant cell formation, mitotic arrest, and a limited degree of apoptosis and necrosis. Within 50 hours of treatment with a combination of radiation and pimozide, cell numbers were sharply reduced compared with cultures exposed to either radiation or pimozide alone. We conclude that pimozide augmented the sensitivity of MCF-7 cells to radiation-induced cell killing through a mechanism not shared by haloperidol, but suggest that concentration of pimozide in MCF-7 cells as a result of an enrichment of sigma 2 sites might target the radiosensitization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9877031     DOI: 10.1023/a:1006046604062

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges.

Authors:  Jin-Ku Lee; DO-Hyun Nam; Jeongwu Lee
Journal:  Oncol Lett       Date:  2016-01-07       Impact factor: 2.967

2.  Inhibition of T-type Ca²⁺ channels by endostatin attenuates human glioblastoma cell proliferation and migration.

Authors:  Yuan Zhang; Junhong Zhang; Dongsheng Jiang; Dong Zhang; Zhiyuan Qian; Chunfeng Liu; Jin Tao
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

3.  T-type Ca2+ channel expression in human esophageal carcinomas: a functional role in proliferation.

Authors:  Fengmin Lu; Hairu Chen; Chun Zhou; Shuang Liu; Mingzhou Guo; Pingping Chen; Hui Zhuang; Dong Xie; Songwei Wu
Journal:  Cell Calcium       Date:  2007-05-25       Impact factor: 6.817

4.  Glioblastoma radiosensitization by pimozide.

Authors:  Barbara H Rath; Kevin Camphausen; Philip J Tofilon
Journal:  Transl Cancer Res       Date:  2016-11       Impact factor: 1.241

5.  Study on the role of transient receptor potential C6 channels in esophageal squamous cell carcinoma radiosensitivity.

Authors:  Yi Zhang; Yongxing Zhang; Hong Fan; Yu Shi; Cheng Zhan; Qun Wang
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.

Authors:  David G Covell
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

7.  The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma.

Authors:  Jia-Jie Chen; Nan Cai; Guan-Zhong Chen; Chang-Chang Jia; Dong-Bo Qiu; Cong Du; Wei Liu; Yang Yang; Zi-Jie Long; Qi Zhang
Journal:  Oncotarget       Date:  2017-03-14

8.  Effect of antipsychotics on breast tumors by analysis of the Japanese Adverse Drug Event Report database and cell-based experiments.

Authors:  Tae Maeshima; Ryosuke Iijima; Machiko Watanabe; Satoru Yui; Fumio Itagaki
Journal:  J Pharm Health Care Sci       Date:  2021-04-01

Review 9.  Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.

Authors:  Vikram Shaw; Suyash Srivastava; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2019-10-13       Impact factor: 15.707

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.